Key result
Triple antithrombotic therapy was an independent predictor for major bleeding complications in patients undergoing PCI (HR 7.25; 95% CI 3.05-17.21; P<0.001), regardless of time in therapeutic range.
Why the study?
Does triple antithrombotic therapy increase major bleeding complications in patients undergoing percutaneous coronary intervention with stent?
Cohort (n=2,648)
Does triple antithrombotic therapy increase major bleeding complications in patients undergoing percutaneous coronary intervention with stent?
Effect estimate: HR 7.25 (95% CI 3.05-17.21)
p-value: p=<0.001
Triple antithrombotic therapy significantly increases the risk of major bleeding complications following PCI, independent of the time in therapeutic range.
No takes yet. Share an insight, caveat, or question.
Urges individualized bleeding risk assessment before triple therapy post-PCI; leaves open whether randomized trials will confirm the association.
Naruse et al. (2013) conducted a cohort in Patients undergoing percutaneous coronary intervention with stent (n=2,648). Triple antithrombotic therapy (dual antiplatelet therapy with warfarin) vs. Dual antiplatelet therapy without warfarin was evaluated on Occurrence of major bleeding complications (MBC) (HR 7.25, 95% CI 3.05-17.21, p=<0.001). Triple antithrombotic therapy was an independent predictor for major bleeding complications in patients undergoing PCI (HR 7.25; 95% CI 3.05-17.21; P<0.001), regardless of time in therapeutic range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: